Epratuzumab is a humanised anti-CD22 monoclonal antibody under investigation (clinical development phase III) for its efficacy in SLE. CD22 is a B cell specific surface protein that is considered to be involved in B cell function.
|Expected indication||Systemic lupus erythematosus|
|R&D stage||Phase 3 ongoing (started in December 2010)|
|Next milestone||Phase 3 results (H1 2014)|
Epratuzumab is a humanized monoclonal antibody. Potential uses may be found inoncology and in treatment of inflammatory autoimmune disorders, such as lupus (SLE). The manufacturers in August 2009 announced success in early trials against SLE.
- Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1…
View original post 962 more words